研究者詳細 - 長谷川　智一

論文 - 長谷川　智一

分割表示 52 件中 21 - 40 件目／全件表示 >>

子宮頸癌根治照射症例におけるCD8の浸潤形式と予後との関連

染谷正則, 土屋高旭, 福島悠希, 長谷川智一, 北川未央, 後町俊夫, 岩崎雅宏, 松浦基樹, 齋藤豪, 坂田耕一

日本癌治療学会学術集会抄録集 ( (一社)日本癌治療学会 ) 59回 O37 - 7 2021年10月

Prediction of treatment response from the microenvironment of tumor immunity in cervical cancer patients treated with chemoradiotherapy.

Masanori Someya, Takaaki Tsuchiya, Yuki Fukushima, Tomokazu Hasegawa, Masakazu Hori, Mio Kitagawa, Toshio Gocho, Shoh Mafune, Yutaro Ikeuchi, Yoshihiko Hirohashi, Toshihiko Torigoe, Masahiro Iwasaki, Motoki Matsuura, Tsuyoshi Saito, Yoshihisa Matsumoto, Koh-Ichi Sakata

Medical molecular morphology 54 ( 3 ) 245 - 252 2021年09月 [国内誌]

To supplement clinical decision-making in the management of cervical cancer, various prognostic factors, including tumor immune microenvironments, were examined in patients with cervical cancer treated with definitive chemoradiotherapy. We retrospectively analyzed the expression of CD8, FoxP3, HLA-1, PD-L1, and XRCC4 in 100 cases of cervical cancer. The observed tumor immune microenvironments were also classified into three types: inflamed, excluded, and cold type. Less FoxP3+ T cells and cold-type tumor were found to be poor prognostic factors in addition to non-SCC, large pre-treatment tumor volume, and three or less cycles of concurrent chemotherapy based on multivariate analysis. Cold-type tumors had significantly worse prognoses than the other two types, whereas inflamed- and excluded-type tumors showed similar 5-year disease-specific survival (P < 0.001; 0% vs. 60.3% vs. 72.3%). Radiotherapy could overcome the inhibitory immune microenvironment that occurs in excluded type. Individualized combination therapy adapted to pre-treatment tumor immunity may be necessary to improve radiotherapy outcomes in cervical cancer.

DOI PubMed

進行食道癌に対するdocetaxel、nedaplatin、5-fluorouracil、放射線併用療法(DNF-R)による根治的化学放射線療法の第I/II相試験-アップデート解析

佐藤昌則, 大沼啓之, 早坂尚貴, 濱口孝太, 村瀬和幸, 高田弘一, 福島悠希, 長谷川智一, 土屋高旭, 染谷正則, 宮西浩嗣, 坂田耕一, 加藤淳二

日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集 ( 日本消化器病学会-北海道支部 ) 129回・123回 26 - 26 2021年09月

肛門管癌に対するS-1+MMCを用いた化学放射線療法

池内佑太郎, 福島悠希, 眞船翔, 小塚陽介, 土屋高旭, 長谷川智一, 堀正和, 染谷正則, 坂田耕一

北海道放射線医学雑誌 ( (NPO)メディカルイメージラボ ) 1 22 - 26 2021年03月

本邦では、肛門管の原発性扁平上皮癌(SCC)は稀な疾患であり、治療方法及び治療成績に関する報告は少ない。現在、肛門管癌に対する化学放射線療法の標準治療は、5-FU+MMC+RTとされており、救済治療として手術が考えられている。5-FUは持続静注投与であり、入院加療が必要となり、そのため、経口剤であるS-1を用いたS-1+MMC+RTの方が、利便性が高いと考える。さらに、S-1は、5-FUのプロドラックであるテガフールと、ギメラシルが含まれている。ギメラシルは、5-FUの肝臓での分解を強力に抑え、結果としてフルオトウラシルを生体内で高濃度かつ長時間維持させる目的でS-1に含有されているが、他施設及び当科の基礎研究でギメラシルの放射線増感があることが示唆されており、それに期待してS-1を使用することとした。今回、当院で肛門管癌(StageI-IIIC(UICC8th))に対してS-1+MMC+RTを施行した9症例に対して検討した。(著者抄録)

食道癌診断と治療のup to date 食道腺癌を含めて切除可能進行食道癌に対する三剤併用療法ベースの化学放射線療法は手術療法を代替できるか?:傾向スコアマッチング分析

大沼啓之, 小野山直輝, 濱口孝太, 早坂尚貴, 佐藤昌則, 村瀬和幸, 高田弘一, 宮西浩嗣, 村上武志, 伊東竜哉, 信岡隆幸, 竹政伊知朗, 土屋高旭, 長谷川智一, 堀正和, 染谷正則, 坂田耕一, 加藤淳二

日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集 ( 日本消化器病学会-北海道支部 ) 128回・122回 35 - 35 2021年03月

根治的放射線治療を受けた子宮頸癌患者におけるCD8細胞浸潤の様態と予後との関連(Relationship between the Type of CD8 Invasion and Prognosis in Patients with Cervical Cancer Treated with Definitive Radiotherapy)

Someya Masanori, Fukushima Yuuki, Tsuchiya Takaaki, Hasegawa Tomokazu, Hori Masakazu, Gocho Toshio, Kozuka Yohsuke, Ikeuchi Yutaro, Mafune Shoh, Sakata Koh-ichi

日本医学放射線学会学術集会抄録集 ( (公社)日本医学放射線学会 ) 80回 S194 - S194 2021年03月

Association between cancer immunity and treatment results in uterine cervical cancer patients treated with radiotherapy.

Masanori Someya, Takaaki Tsuchiya, Yuki Fukushima, Tomokazu Hasegawa, Yu Takada, Masakazu Hori, Katsutoshi Miura, Mio Kitagawa, Toshio Gocho, Yoshihiko Hirohashi, Toshihiko Torigoe, Masahiro Iwasaki, Motoki Matsuura, Tsuyoshi Saito, Koh-Ichi Sakata

Japanese journal of clinical oncology 50 ( 11 ) 1290 - 1297 2020年10月 [国際誌]

OBJECTIVE: To evaluate proteins related to tumor immune response and treatment outcome from radiotherapy for uterine cervical cancer patients. METHODS: We performed a retrospective immunohistochemical staining of 81 patients with uterine cervical cancer who underwent definitive radiotherapy. We examined the expression of programmed death ligand 1, human leukocyte antigen class I, tumor-infiltrating CD8+, and forkhead box P3+ (FoxP3+) T cells in tumor tissues. RESULTS: In biopsy specimen, patients with a higher number of CD8+ T cells and FoxP3+ T cells had a better disease-specific survival than patients with a lower number of CD8+ T cells and FoxP3+ cells (P = 0.018 and P = 0.009). Multivariate analysis showed that equivalent dose in 2 Gy fractions (EQD2) of the minimum dose to 90% of the high-risk clinical target volume, FoxP3+ T cells and expression of human leukocyte antigen class I were significant prognostic factors. When the EQD2 is 70 Gy or more, a higher local control rate is obtained regardless of the number of CD8- or FoxP3-positive cells. When EQD2 is <70 Gy, the number of CD8-positive cells has a significant impact on treatment outcome: the recurrence rate (local recurrence rate + distant metastasis rate) was 46.2% in the group with a CD8 value of 230 or higher, whereas the recurrence rate was 75.7% in the group with a CD8 value of less than 230. CONCLUSION: The combination of CD8 or FoxP3 with EQD2 can be potentially useful to predict the treatment results of radiotherapy for cervical cancer, leading to individualized optimal selection of treatment for cervical cancer.

DOI PubMed

根治放射線療を行った進行期子宮頸癌症例における腫瘍免疫と予後の関連

染谷正則, 土屋高旭, 福島悠希, 長谷川智一, 高田優, 中田健生, 堀正和, 三浦勝利, 北川未央, 後町俊夫, 岩崎雅宏, 松浦基樹, 齋藤豪, 坂田耕一

日本癌治療学会学術集会抄録集 ( (一社)日本癌治療学会 ) 58回 O16 - 4 2020年10月

Association between radiotherapy-induced alteration of programmed death ligand 1 and survival in patients with uterine cervical cancer undergoing preoperative radiotherapy.

Takaaki Tsuchiya, Masanori Someya, Yu Takada, Tomokazu Hasegawa, Mio Kitagawa, Yuki Fukushima, Toshio Gocho, Masakazu Hori, Kensei Nakata, Yoshihiko Hirohashi, Toshihiko Torigoe, Tsuyoshi Saito, Koh-Ichi Sakata

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] 196 ( 8 ) 725 - 735 2020年08月 [国際誌]

PURPOSE: To evaluate radiotherapy-induced changes in the expression of programmed death ligand 1 (PD-L1), programmed death 1 (PD-1), and human leukocyte antigen class I (HLA-1) in patients with uterine cervical cancer, as well as infiltration of CD8+ and Forkhead box P3+ (FoxP3+) T lymphocytes into tumor tissue and the prognostic value of these parameters. MATERIALS AND METHODS: We performed immunohistochemical analysis of pre-radiotherapy biopsies and corresponding post-radiotherapy resected tissues in 104 uterine cervical cancer patients undergoing preoperative chemoradiotherapy or radiotherapy alone. We scored the expression of various proteins to distinguish positive from negative samples. RESULTS: PD-L1-expressing tumor cells (PD-L1 TC) increased significantly after chemoradiotherapy (p = 0.043). CD8+ T cell infiltration (p = 0.002) and FoxP3+ T cell infiltration (p = 0.003) decreased significantly after chemoradiotherapy. Expression of PD‑1, PD-L1-expressing immune cells (PD-L1 IC), and HLA‑1 did not change after chemoradiotherapy. In biopsy specimens obtained before chemoradiotherapy or radiotherapy, greater infiltration of CD8+ T cells (p = 0.001) and FoxP3+ T cells (p = 0.003) were significant predictors of better overall survival (OS). In surgical specimens obtained after chemoradiotherapy or radiotherapy, greater infiltration of PD-L1 TC was the only significant predictor of better OS (p < 0.001) and was related to a significantly lower probability of out-of-field recurrence (p = 0.005). CONCLUSION: Chemoradiotherapy induced an immunologic shift that increased PD-L1 TC. Chemoradiotherapy has immunological effects that can influence the results of treatment for uterine cervical cancer.

DOI PubMed

Evaluation of the urethral α/β ratio and tissue repair half-time for iodine-125 prostate brachytherapy with or without supplemental external beam radiotherapy

Toshio Gocho, Masakazu Hori, Yuuki Fukushima, Masanori Someya, Mio Kitagawa, Tomokazu Hasegawa, Takaaki Tsuchiya, Masato Hareyama, Masaru Takagi, Kohei Hashimoto, Naoya Masumori, Koh-ichi Sakata

Brachytherapy ( Elsevier BV ) 19 ( 3 ) 290 - 297 2020年05月

PURPOSE: To assess the correlation between postimplant dosimetric quantifiers and the genitourinary (GU) toxicity of low-dose rate brachytherapy for prostate cancer.METHODS AND MATERIALS: The minimum urethral dose (UD10, 30, and 90) and the percent volume of the urethra receiving the prescription dose (V100, V150) were calculated from the post-implant dose-volume histograms of 182 patients. We then calculated various urethral biologically equivalent doses (uBEDs) using different values of the alpha/beta ratio and tissue repair half-time (t1/2) and examined the correlations with GU toxicity.RESULTS: Common dosimetric quantifiers, such as UD90 (brachytherapy) + UD50 (external beam radiotherapy), showed no correlation with Grade >= 2 GU toxicity. There was a significant correlation between Grade GU toxicity and uBED when the alpha/beta value was 0.5 or 1 Gy and t1/2 was 0.5-2.5 h. An uBED (alpha/beta = 1.0, t1/2 = 0.5) had the largest hazard ratio for GU toxicity, and it was also significantly correlated with Grade >= 2 GU toxicity according to multivariate analysis.CONCLUSIONS: We observed a significant correlation of uBED with GU toxicity when alpha/beta was 0.5 or 1.0 Gy and t1/2 was 0.5-2.5 h. As the simple formula we used has not been verified in basic experiments, more data are needed to validate our results. (C) 2020 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.

DOI

Retrospective DVH analysis of point A based intracavitary brachytherapy for uterine cervical cancer.

Masanori Someya, Tomokazu Hasegawa, Takaaki Tsuchiya, Mio Kitagawa, Toshio Gocho, Yuuki Fukushima, Masakazu Hori, Katsutoshi Miura, Yu Takada, Kensei Nakata, Koh-Ichi Sakata

Journal of radiation research 61 ( 2 ) 265 - 274 2020年03月 [国際誌]

Combining external beam radiotherapy (EBRT) with intracavitary brachytherapy (ICBT) is important for definitive treatment of cervical cancer. In cervical cancer patients receiving radiotherapy, we evaluated treatment outcomes in relation to dose-volume histogram parameters, including the computed tomography (CT)-based high-risk clinical target volume (HR-CTV) for ICBT. Between 2010 and 2015, 89 consecutive cervical cancer patients were mostly treated with 40 Gy of EBRT in 20 fractions and 18 Gy of ICBT prescribed to point A in 3 fractions. CT scans were obtained during ICBT. The HR-CTV D90 was calculated and the total doses of ICBT and EBRT were converted to the equivalent dose in 2 Gy fractions (EQD2). When the patients were divided into four groups according to EQD2 of the HR-CTV D90, the 3-year local recurrence-free survival rates were 95.2, 78.4, 52.7 and 42.9% for patients receiving >80 , 70-80 , 60-70 and <60 Gy, respectively. There was a significant negative correlation between EQD2 of the HR-CTV D90 and the HR-CTV volume at first ICBT (r = -0.713). Local recurrence was more frequent when the HR-CTV volume was ≥22 cc and EQD2 of the HR-CTV D90 was <70 Gy. Multivariate analysis showed that EQD2 of the HR-CTV D90 and concurrent chemotherapy (≥4 cycles) were significant determinants of overall survival. HR-CTV D90 was an important prognostic indicator for local recurrence. HR-CTV D90 >70 Gy is required for the better local control, especially in patients with a larger HR-CTV (≥22 cc at initial ICBT).

DOI PubMed

切除可能進行食道癌に対する三剤併用療法ベースの化学放射線療法は手術療法を代替できるか? 傾向スコアマッチング分析

大沼啓之, 小野山直輝, 濱口孝太, 早坂尚貴, 佐藤昌則, 村瀬和幸, 高田弘一, 宮西浩嗣, 伊東竜哉, 信岡隆幸, 竹政伊知朗, 長谷川智一, 堀正和, 染谷正則, 坂田耕一, 加藤淳二

日本消化器病学会北海道支部例会プログラム・抄録集 ( 日本消化器病学会-北海道支部 ) 126回 50 - 50 2020年03月

放射線治療を施行した進行子宮頸癌患者における腫瘍免疫と生存の関連性(Association between tumor Immunity and survival in patients with advanced uterine cervical cancer treated with raiotherapy)

Someya Masanori, Hasegawa Tomokazu, Tsuchiya Takaaki, Fukushima Yuuki, Kitagawa Mio, Hori Masakazu, Sakata Koh-ichi, Takada Yu, Nakata Kensei, Miura Katsutoshi

日本医学放射線学会学術集会抄録集 ( (公社)日本医学放射線学会 ) 79回 S176 - S176 2020年02月

Influence of XRCC4 expression by breast cancer cells on ipsilateral recurrence after breast-conserving therapy.

Mio Kitagawa, Masanori Someya, Tomokazu Hasegawa, Toshihiko Mikami, Kazuaki Asaishi, Tadashi Hasegawa, Yoshihisa Matsumoto, Goro Kutomi, Ichiro Takemasa, Koh-Ichi Sakata

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] 195 ( 7 ) 648 - 658 2019年07月 [国際誌]

BACKGROUND: We examined the expression of nonhomologous end-joining (NHEJ) proteins by breast cancer cells in patients with or without ipsilateral breast tumor recurrence (IBTR) after breast-conserving therapy. We also investigated whether there was a difference of NHEJ-related protein expression by tumor cells between two types of IBTR, i.e., true recurrence (TR) with regrowth from the tumor bed or development of a new primary tumor (NP). PATIENTS AND METHODS: The original cohort comprised 560 breast cancer patients who received breast-conserving therapy between February 1995 and March 2006, including 520 patients without IBTR and 40 patients with IBTR. Propensity score matching was employed to select 40 trios (120 patients) consisting of 1 patient with IBTR and 2 patients without IBTR. Immunohistochemical examination of proteins related to NHEJ was performed in surgical specimens. RESULTS: The 40 patients with IBTR included 22 patients who developed TR and 18 who had NP. The 15-year overall survival rate was 85.9% for patients with NP and 95.5% for those with TR, while it was 96.5% for patients without IBTR. Patients with high XRCC4 expression in tumor cells had significantly higher IBTR rates than those with low XRCC4 expression (P < 0.001). The frequency of TR was significantly higher in patients with high expression of XRCC4 than in those with low XRCC4 expression (p < 0.001). XRCC4 expression by tumor cells was not significantly related to development of NP. CONCLUSION: IBTR due to TR may be related to low radiosensitivity of tumor cells, possibly related to high XRCC4 expression.

DOI PubMed

当院で腔内照射を施行した子宮頸癌の線量解析(DVH Analysis of Intracavitary Brachytherapy for Uterine Cervical Cancer)

Someya Masanori, Hasegawa Tomokazu, Tsuchiya Takaaki, Kitagawa Mio, Gocho Toshio, Fukushima Yuuki, Takada Yu, Miura Katsutoshi, Hori Masakazu, Sakata Koh-ichi

日本医学放射線学会学術集会抄録集 ( (公社)日本医学放射線学会 ) 78回 S264 - S264 2019年02月

Influence of PD-L1 expression in immune cells on the response to radiation therapy in patients with oropharyngeal squamous cell carcinoma.

Yuki Fukushima, Masanori Someya, Kensei Nakata, Masakazu Hori, Mio Kitagawa, Tomokazu Hasegawa, Takaaki Tsuchiya, Toshio Gocho, Hikaru Ikeda, Yoshihiko Hirohashi, Toshihiko Torigoe, Shintaro Sugita, Tadashi Hasegawa, Tetsuo Himi, Koh-Ichi Sakata

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 129 ( 2 ) 409 - 414 2018年11月 [国際誌]

BACKGROUND AND PURPOSE: To investigate influences of proteins involved with tumor immunity on outcomes of radiotherapy for oropharyngeal squamous cell carcinoma (OPSCC). MATERIAL AND METHODS: We performed immunohistochemical staining to examine expressions of p16 and proteins involved with tumor immunity in 92 OPSCC patients treated with radiotherapy. RESULTS: Patients with abundant infiltrating CD8-positive cells had the significantly better overall survival (OS) rate than patients with fewer CD8-positive cells (p = 0.026). Patients with higher PD-L1 expression in tumor cells (TC 1-3) had a better outcome than those with low PD-L1 expression in tumor cells (TC 0) for both OS (p = 0.019) and progression-free survival (PFS) rate (p = 0.032). Patients with high PD-L1 expression in infiltrating immune cells (IC 3) showed significantly better OS (p = 0.009) and PFS (p = 0.011) than those with low PD-L1 expression (IC 0-2). Patients with p16-negative and IC 3 showed similar OS to patients with p16-positive and IC 0-2. P16-positive tumors had a significantly higher CD8-positive cell infiltration and PD-L1 expression in tumor cells than p16-negative tumors. CONCLUSIONS: In addition to tumor p16 expression, PD-L1 expression in TC and IC can be useful for predicting the response of OPSCC to radiotherapy.

DOI PubMed

Prediction of acute gastrointestinal and genitourinary radiation toxicity in prostate cancer patients using lymphocyte microRNA.

Masanori Someya, Masakazu Hori, Toshio Gocho, Kensei Nakata, Takaaki Tsuchiya, Mio Kitagawa, Tomokazu Hasegawa, Yuuki Fukushima, Koh-Ichi Sakata

Japanese journal of clinical oncology 48 ( 2 ) 167 - 174 2018年02月 [国際誌]

Background: To search for novel biomarkers that can predict acute radiation toxicity, we conducted microRNA expression analysis of peripheral blood lymphocytes (PBLs). Methods: The discovery cohort was 69 patients with localized adenocarcinoma of the prostate who received intensity-modulated radiation therapy between October 2007 and October 2010. The validation cohort was 72 patients treated with low-dose-rate brachytherapy between May 2008 and March 2014. After13 microRNAs were selected by TaqMan® Array analysis in a preliminary experiment, expression of these microRNAs in all samples was analyzed by RT-PCR. Results: In the discovery cohort, the average prostate volume, the rectal volume receiving 70 Gy, and expression of miR-410 and miR-221 were significant risk factors for Grade 1-2 gastrointestinal toxicity. Receiver operating characteristic analysis showed that the area under the curve (AUC) was 0.807. The maximum dose to the urinary bladder, prostate volume, pretreatment urinary function score, and miR-99a and miR-221 expression were risk factors for Grade 2 genitourinary toxicity. The corresponding AUC was 0.796. In the validation cohort, reproducibility of these markers was confirmed for gastrointestinal toxicity, but not for genitourinary toxicity. Conclusion: Combining radiation dose parameters with microRNA expression in PBLs may be useful for predicting acute gastrointestinal toxicity of radiation therapy, thus contributing to personalized treatment of prostate cancer.

DOI PubMed

子宮頸癌の放射線治療成績と末梢血リンパ球のDNA-PK活性の関係

染谷正則, 松本健一, 福島悠希, 後町俊夫, 土屋高旭, 長谷川智一, 北川未央, 堀正和, 中田健生, 坂田耕一

Japanese Journal of Radiology ( (公社)日本医学放射線学会 ) 36 ( Suppl. ) 11 - 11 2018年02月

中咽頭癌の治療成績ならびにHPV感染と免疫染色の関連性

福島悠希, 染谷正則, 中田健生, 堀正和, 北川未央, 土屋高旭, 長谷川智一, 後町俊夫, 松本健一, 坂田耕一

Japanese Journal of Radiology ( (公社)日本医学放射線学会 ) 36 ( Suppl. ) 10 - 10 2018年02月

　前のページ - 次のページ　

<長谷川 智一>

論文 - 長谷川 智一

<長谷川　智一>

論文 - 長谷川　智一